27963
蓖麻油，乙氧基化
别名:
Cremophor® EL, PEG-35蓖麻油, 乙氧基化蓖麻油, 聚甲醛-35蓖麻油
InChI
1S/C4H7Cl2NO2/c5-1-3(2-6)9-4(7)8/h3H,1-2H2,(H2,7,8)
InChI key
JMNCUXPHXKHBPY-UHFFFAOYSA-N
description
non-ionic
density
1.05 g/mL at 20 °C
application(s)
sample preservation
正在寻找类似产品? 访问 产品对比指南
Other Notes
是蓖麻油和环氧乙烷的一种衍生物。
This product has been replaced by C5135-SIGMA | Kolliphor EL pH-range 6.0 - 8.0
Legal Information
Cremophor is a registered trademark of BASF SE
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
494.6 °F - Not applicable
flash_point_c
257 °C - Not applicable
ppe
Eyeshields, Gloves
法规信息
新产品
此项目有
Eiki Goto et al.
Ophthalmology, 109(11), 2030-2035 (2002-11-05)
We developed low-concentration homogenized castor oil eye drops for the treatment of patients with noninflamed obstructive meibomian gland dysfunction (MGD), a major cause of lipid-deficiency dry eye, and assessed the safety, stability, and efficacy of the eye drops. Randomized, double-masked
Shu Yu et al.
Vaccine, 30(36), 5425-5436 (2012-06-20)
Oil-in-water emulsions are potent human adjuvants commonly used in effective pandemic influenza vaccines; however, such emulsions that can induce both Th1-biased systemic immune responses and strong mucosal immune responses via an easy method of administration are lacking. To address this
Yukako Ito et al.
Journal of drug targeting, 13(6), 383-390 (2005-11-10)
Interferon alpha (IFN-alpha), patch preparations composed of three layers, water-insoluble backing layer, drug containing layer with absorption enhancer and surface layer containing pH-dependent polymer were prepared. As absorption enhancer, three surfactants, Gelucire44/14 (Lauroyl macrogol-32 glycerides), Labrasol (Caprylocaproyl macrogol-8 glycerides) and
William J Gradishar et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(31), 7794-7803 (2005-09-21)
ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor oil-based standard paclitaxel in patients with metastatic breast cancer (MBC). This phase III study was performed to confirm preclinical studies demonstrating
Nuhad K Ibrahim et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8(5), 1038-1044 (2002-05-15)
ABI-007 is a novel Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. The absence of Cremophor EL may permit ABI-007 to be administered without the premedications used routinely for the prevention of hypersensitivity reactions. Furthermore, this novel formulation permits a higher paclitaxel
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持